| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Ovarian cancer remains the most lethal gynecologic malignancy, largely due to the lack of effective chemotherapeutic agents in the setting of platinum resistant disease. Chemotherapeutic agents targeting critical molecular pathways hold promise for improving survival in these patients. Understanding the critical molecular pathways is central to the development of such agents. With digital karyotyping, we discovered a new amplified oncogene, NAC-1. Repression of NAC-1 induced apoptosis of ovarian cancer cells.NAC-1 dimerization is integral to its function. Based on the structural analysis of the NAC-1 BTB domain, we screened candidate inhibitors of NAC-1 dimer formation.We have begun development on a carcinogenic mouse model of NAC-1 in which inhibitors will be tested prior to being introduced in the clinical setting.
|
